Exelixis-Phase 2 Study of Zanzalintinib in Recurrent or Progressive Meningioma (XL092-201) - Clinical Trial
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
A Phase 2, Single-Arm, Multicenter, Open-Label Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma (XL092-201)
Principal Investigator
Katherine B. Peters, MD, PhD
Neuro-oncologist
Protocol Number
IRB:
PRO00119908
NCT:
NCT07428616
Phase
Phase II
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Call 919-684-5301